(813) 971-8080

7210 Wareham Drive, Tampa, FL 33647

commercial weight loss

Weight Watchers Hires New International V.P.

Sept. 3, 2025 WW announced the appointment of Alejandro Bethlen as Executive Vice President, International, effective immediately. In this role, Bethlen will oversee WeightWatchers’ business outside of the United States, driving international growth and innovation across the Company’s global footprint. “Alejandro’s international experience and commercial leadership make him uniquely suited to advance our growth outside

Weight Watchers Hires New International V.P. Read More »

Novo Nordisk Obesity Drugs Sales Slow – Compounders Still Selling illegally

August 6, 2025 Sales of Novo Nordisk’s injectable diabetes drugs including Ozempic have slowed sharply amid fierce competition and the threat of U.S. tariffs, coupled with continued competition from compounded drugs sold illegally. Novo Nordisk said sales of medications such as Ozempic – which mimic the GLP-1 gut hormone that regulates blood sugar levels and

Novo Nordisk Obesity Drugs Sales Slow – Compounders Still Selling illegally Read More »

Weight Watchers Expands Collaboration With Novo Nordisk

July 2, 2025 Weight Watchers announced an expanded collaboration with Novo Nordisk, which includes increased access to authentic, FDA-approved Wegovy® (semaglutide) injection through Weight Watchers Clinic. As part of the collaboration, Weight Watchers Clinic members will benefit from a simplified prescription process via NovoCare® Pharmacy. CenterWell Pharmacy®, which serves as the dispensing pharmacy for the

Weight Watchers Expands Collaboration With Novo Nordisk Read More »

$38.4 Billion U.S. Commercial Weight Loss Market Pivots To Survive GLP-1 Drugs Explosion

March 24, 2025 Marketdata LLC has just published a new report: “The U.S. Weight Loss Market: Commercial (non-medical) Programs & Products”, March 2025. This is a 220-page analysis of commercial weight loss programs/companies and how they have been affected by and respond to the onslaught of the GLP-1 drugs competition. The $38 billion U.S. commercial weight loss

$38.4 Billion U.S. Commercial Weight Loss Market Pivots To Survive GLP-1 Drugs Explosion Read More »

Scroll to Top